Patritumab Deruxtecan clinical trials
6 indexed studies · 4 currently recruiting
- Active not recruitingPHASE3
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
This study looks at a new drug, patritumab deruxtecan, for a type of lung cancer that has stopped responding to standard treatments. It compares this new drug with traditional chemotherapy to see if it works better and is safer for patients.
For: Nonsquamous Non-small Cell Lung Cancer · EGFR L858R · EGFR Exon 19 DeletionUnited States · Australia · Austria - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
For: Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
This study looks into a new medicine, patritumab deruxtecan, for HER2-positive breast cancer that has spread and can't be removed by surgery. Researchers want to see if it's safe, how well people tolerate it, and if it can shrink or get rid of the cancer.
For: Breast Neoplasms · Breast CancerUnited States · Canada · Israel - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER3-EXPRESSING ADVANCED BREAST CANCER AND NON–SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL CARCINOMATOSIS FROM HER3-EXPRESSING ADVANCED SOLID TUMORS (The TUXEDO-3 Study)
This study looks at a new drug called Patritumab deruxtecan for advanced breast or lung cancer that has spread to the brain, or for other advanced solid cancers that have spread to the brain lining. It aims to see how well the drug shrinks tumors and helps people live longer.
For: Metastatic Breast Cancer or Advanced Non-Small Cell Lung Cancer with asymptomatic untreated or progressing Brain Metastases, or solid tumors with Leptomeningeal diseaseAustria · Spain - RecruitingPHASE1, PHASE2
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
This study is looking for new ways to treat specific childhood cancers that have come back or not responded to previous treatments. It investigates a new medicine called HER3-DXd (also known as patritumab deruxtecan) for safety and effectiveness in children aged 1 month to 17 years with hepatoblastoma or rhabdomyosarcoma.
For: Malignant NeoplasmUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This study looks at new drug combinations with a medicine called pembrolizumab and chemotherapy for advanced stomach or oesophageal cancer that can't be removed by surgery. It's in early stages (Phase 1/2) and aims to find safe doses and see how well the treatments work.
For: Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal NeoplasmsUnited States · Brazil · Chile